Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan
Subject: Antiviral (oral/topical) Agents
Status
Drug
PR
PR-QL
PR-AL
ST
M EX‡
P
acyclovir oral
P
ganciclovir
P
Valcyte®(valganciclovir)
P
Valtrex®(valacyclovir)
NP
Cytovene®(ganciclovir)
FE
Denavir ®(penciclovir, topical cream)
X
FE
Famvir®(famciclovir)
X
FE
Zovirax®(acyclovir, oral, topical ointment)
X
Policy:
Medical Exception Criteria
Famvir, Zovirax and Denavir are currently listed on the Aetna Formulary Exclusions List.* Therefore, Famvir, Zovirax and Denavir are excluded from coverage for members enrolled in prescription drug benefit plans that use a closed formulary, unless a medical exception is granted. Aetna considers Famvir, Zovirax and Denavir to be medically necessary for those members who meet any of the following criteria:
A documented:
Contraindication to one preferred alternative indicated for the member's condition OR,
Intolerance to one preferred alternative indicated for the member's condition OR,
Allergy to one preferred alternative indicated for the member's condition OR
Failure of an adequate trial of one week of one preferred alternative indicated for the member's condition.
Place of Service:
Outpatient
The above policy is based on the following references:
Product Information, Famvir tablets, Novartis Pharmaceuticals, East Hanover, NJ, February 2002.
Olin BR, editor.Drug Facts and Comparisons (online version). St Louis: J.B.Lippincott Company, Facts and Comparisons division, 2006.
McEvoy GK, editor. AmericanHospitalFormulary Service Drug Information 2004. STAT!Ref Online Electronic Medical Library Bethesda, MD: The American Society of Health-System Pharmacists, Inc, 2006.
Medispan Drug Information 2006.
USPDI Drug Information for the HealthCare Professional(online through Stat!Ref). Thomson MICROMEDEX, Greenwood Village, Colorado; 2006.
Global epidemiology of genital herpes and the interaction of herpes simplex virus with HIV. In: Corey L, ed. HERPES: the Journal of the IFHM. 2004;11(Suppl 1).
LawrenceCorey, MD,Clinical Tools for Preventing Sexual Transmission of Genital Herpes; Medscape Infectious Diseases 6(1), 2004.
Product Information, Denavir cream, Novartis Pharmaceuticals, East Hanover, NJ, October 2003.
Product Information, Zovirax ointment, GlaxoSmithKline, Research Triangle Park, NC, May 2001
The Medical Letter. Drugs for Non-HIV Viral Infections. Vol. 44, February 4, 2002
Evans, T, et. al, Double-Blind, Randomized, Placebo-controlled Study of Topical 5% Acyclovir-1% Hydrocortisone Cream (ME-609) for Treatment of UV Radiation-induced Herpes Labialis. Antimicrob Agents Chemother 2002; 46:1870-4
Chen X, et. al, A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial. Int J STD AIDS 2000; 11:568-73
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
*P = Preferred
FE = Formulary Excluded
NP = Nonpreferred
PR = Precertification
QL = Quantity Limits
AL = Age Limits
ST = Step-Therapy
‡M EX = Medical Exception
*The lists above are subject to change. Not all programs - for example step-therapy, precertification, and quantity limits - are available in all service areas.